Based on the information available, the recommended delay for live vaccines after Cosentyx (secukinumab) treatment is not explicitly stated in the drug's prescribing information or official resources. However, it is generally recommended to avoid live vaccines during immunosuppressive therapy due to the potential risk of vaccine-induced infection [1].

Cosentyx, a human interleukin-17A inhibitor, is used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The drug's prescribing information does not provide specific guidance on the timing of live vaccinations [1].

However, the drug's manufacturer, Novartis, states that "the safety of Cosentyx in patients with a chronic infection or a history of chronic or recurrent infection has not been established" [1]. This statement suggests that caution should be exercised when administering live vaccines during Cosentyx treatment.

In a study published in the Journal of Dermatological Treatment, the authors mention that "live vaccines should be avoided during treatment with biologic agents" [2]. This recommendation is based on the potential risk of infection associated with immunosuppressive therapy.

In summary, while there is no specific recommended delay for live vaccines after Cosentyx treatment, it is generally advised to avoid live vaccines during immunosuppressive therapy due to the potential risk of vaccine-induced infection. It is crucial to consult a healthcare professional for personalized advice on vaccinations during Cosentyx treatment.

Sources:
[1] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) [Prescribing Information]. 2021. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.
[2] Reich K, Kopp T, Reich A, et al. Secukinumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2017;28(8):715-724. doi:10.1080/09546634.2017.1316755. <https://www.tandfonline.com/doi/full/10.1080/09546634.2017.1316755>.

(Note: DrugPatentWatch.com was not used as a source in this response.)